Hannah Kaminski, Gabriel Marseres, Nathalie Yared, Marie-Julie Nokin, Vincent Pitard, Atika Zouine, Isabelle Garrigue, Séverine Loizon, Myriam Capone, Xavier Gauthereau, Maria Mamani-Matsuda, Roxane Coueron, Raúl V Durán, Benoît Pinson, Isabelle Pellegrin, Rodolphe Thiébaut, Lionel Couzi, Pierre Merville, Julie Déchanet-Merville
BACKGROUND: The reported association of mTOR-inhibitor (mTORi) treatment with a lower incidence of cytomegalovirus (CMV) infection in kidney transplant recipients (KTR) who are CMV seropositive (R+) remains unexplained. METHODS: The incidence of CMV infection and T-cell profile was compared between KTRs treated with mTORis and mycophenolic acid (MPA), and in vitro mTORi effects on T-cell phenotype and functions were analyzed. RESULTS: In KTRs who were R+ and treated with MPA, both αβ and γδ T cells displayed a more dysfunctional phenotype (PD-1+, CD85j+) at day 0 of transplantation in the 16 KTRs with severe CMV infection, as compared with the 17 KTRs without or with spontaneously resolving CMV infection...
January 2022: Journal of the American Society of Nephrology: JASN